Should You Invest in This Dividend King on the Dip?

Johnson & Johnson reported strong Q3 results with revenue beating expectations and raised full-year guidance, driven by excellent pharmaceutical segment performance including cancer drug Darzalex and autoimmune treatment Tremfya. However, the medtech division underperformed, particularly due to safety concerns with Impella heart pumps. Despite near-term headwinds, the article argues J&J remains a solid long-term buy given its robust pharmaceutical pipeline, upcoming medtech innovations like robotic surgery devices, and its status as a Dividend King with 64 consecutive years of dividend increases.